Diego Mastronardi, MD
Family Medicine · Bowling Green, KYNPI 1104822626
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 548 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 548 payments — averaging $15.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Boehringer Ingelheim$1K
- Novo Nordisk$980
- Amgen$883
- AstraZeneca$819
- Pfizer$654
- plus $3K from 37 others
Across 19 payments — averaging $9853.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Travere Therapeutics, Inc.$114K
- AstraZeneca$74K
What the payments were for
- Food & beverage$8,23298%
- Education$1922%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,424 in reported general payments places this provider in the 90th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 149 | $139,311 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 61 | $72,640 |
| TrulicityDulaglutide | 49 | $69,059 |
| EliquisApixaban | 53 | $50,946 |
| JardianceEmpagliflozin | 58 | $46,860 |
| MounjaroTirzepatide | 35 | $40,446 |
| XareltoRivaroxaban | 27 | $35,717 |
| FarxigaDapagliflozin Propanediol | 18 | $26,290 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $24,620 |
| OxycontinOxycodone Hcl | 13 | $23,306 |
| MyrbetriqMirabegron | 13 | $15,222 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 18 | $13,823 |
| SynthroidLevothyroxine Sodium | 114 | $6,905 |
| Mirabegron ErMirabegron | 11 | $6,767 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $6,734 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSynjardy Xr, Jardiance, Stiolto Respimat, Glyxambi | $1,118 | $139,546149 claims |
| Novo NordiskOzempic | $980 | $139,311149 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $265 | $109,50484 claims |
| PfizerEliquis | $654 | $50,94653 claims |
| Johnson & JohnsonXarelto | $59 | $35,71727 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $337 | $27,63530 claims |
| AstraZenecaFarxiga | $819 | $26,29018 claims |
| Astellas Pharma US IncMyrbetriq | $89 | $15,22213 claims |
| AbbVieSynthroid | $1,226 | $6,905114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Bowling Green
- John TappBowling Green$25K
- James DouglasBowling Green$10K
- Christopher RhyneLouisville$933K
- John RichardLexington$226K
- James TurnboPaducah$124K
- Edward SchumannFlorence$79K
- Ronald KoffNew Castle$71K
- Suraj GathaniLouisville$69K
- Bradley GrayFlorence$51K
- Jackie KazeeAshland$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.